

Gene Therapy

Part I: Technologies & Markets

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech. Prof. Jain's 470 publications include 27 books (5 as editor + 22 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011; 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition. Chemical Industry Press 2016, 2nd ed Springer 2017) and "Handbook of Neuroprotection" (Springer 2011). Books that contain chapters on gene therapy include: Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and Applications of Biotechnology in Oncology (Springer 2014). He has also edited "Applied Neurogenomics" (Springer in 2015).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of Neurological Disorders was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supercedes and updates all the previous books as well as reports.

September 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical evolution of gene therapy	23
Relation of gene therapy to other biotechnologies.....	25
Molecular biological basics for gene therapy	26
Genome.....	26
DNA	26
RNA	27
<i>Alternative RNA splicing.....</i>	<i>28</i>
Genes.....	28
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation	29
Gene expression	30
ENCODE	31
Chromosomes	32
Telomeres.....	32
Mitochondria	32
Proteins	33
2. Gene Therapy Technologies	35
Classification of gene therapy techniques.....	35
Ex vivo and in vivo gene therapy	36
Ex vivo gene therapy.....	36
In vivo gene therapy	37
Physical methods of gene transfer.....	37
Electroporation	37
Applications of electroporation	38
<i>Clinical applications of electroporation</i>	<i>39</i>
<i>Advantages of electroporation</i>	<i>39</i>
<i>Limitations of electroporation</i>	<i>40</i>
Hydrodynamic	40
Microinjection	40
Particle bombardment	41
Ultrasound-mediated transfection	42
Molecular vibration.....	43
Application of pulsed magnetic field and superparamagnetic nanoparticles	43
Gene transfection using laser irradiation	44
Photochemical transfection.....	44
Chemical methods of gene transfer	45
Gene repair and replacement.....	45
Gene repair by single-stranded oligonucleotides.....	45
History and current status of chimeraplasty	46
Genome editing.....	46
Gene editing by use of short synthetic oligonucleotides.....	46
Genome engineering by using TALENs	46
Targeted genome editing by artificial nucleases	47
Clinical applications of gene editing	47
Genome editing by using CRISPR system	47
<i>A method for generating genome-wide gRNA libraries for CRISPR.....</i>	<i>49</i>
<i>CRISPER system for creating animal models of human diseases.....</i>	<i>49</i>
<i>CRISPR/Cas9 technology for drug discovery</i>	<i>50</i>
<i>Expanding the range of Cas9s</i>	<i>50</i>
<i>Inducible CRISPR/Cas9 for multiple gene targeting</i>	<i>50</i>
<i>Photoactivatable CRISPR-Cas9.....</i>	<i>50</i>
<i>Protein delivery and genome editing.....</i>	<i>51</i>
<i>Potential clinical applications of CRISPR systems.....</i>	<i>51</i>
<i>PERV blockage by CRISPR to facilitate xenotransplantation</i>	<i>52</i>
<i>RNA alteration by CRISPR</i>	<i>52</i>
<i>Clinical trial of CRISPR in human cancer.....</i>	<i>53</i>
<i>Complications and limitations of CRISPR/Cas9 technology.....</i>	<i>53</i>
<i>Companies developing CRISPR technology</i>	<i>54</i>
mRNA gene therapy	54
Spliceosome mediated RNA trans-splicing	54
Vectors for gene therapy	55
Basic considerations	55

Use of genes as pharmaceuticals	56
The ideal vector for gene therapy.....	56
Viral vectors.....	57
<i>Adenovirus vectors</i>	58
<i>Adeno-associated virus vectors</i>	60
<i>Alphavirus vectors</i>	63
<i>Baculovirus vectors</i>	63
<i>Foamy virus vectors</i>	64
<i>Herpes simplex virus vectors</i>	64
<i>Lentiviral vectors</i>	66
<i>Multicistronic retroviral vectors</i>	67
<i>Retroviral vectors</i>	68
<i>Oncogenic potential of retroviral vectors</i>	69
<i>Quantification of viral vectors</i>	70
<i>Future prospects of viral vectors</i>	70
<i>Companies using viral vectors</i>	71
Nonviral vectors for gene therapy	72
<i>Anionic lipid-DNA complexes</i>	73
<i>Cationic lipid-DNA complexes</i>	73
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	74
<i>Electrostatic modifications of surface to improve gene delivery</i>	74
<i>Liposomes for gene therapy</i>	74
<i>Liposome-nucleic acid complexes</i>	76
<i>Liposome-HVJ complex</i>	76
<i>Transposons DNA vectors</i>	76
<i>Polycation-DNA complexes (polyplexes)</i>	77
<i>Plasmid DNA vs minicircle DNA</i>	78
<i>Polymer vectors for gene therapy</i>	79
<i>Synthetic biology and DNA vectors</i>	79
<i>Synthetic peptide complexes</i>	80
<i>Future prospects of nonviral vs viral vectors</i>	80
Nanobiotechnology for gene therapy	81
<i>Antisense nanoparticles</i>	81
<i>Dendrimers</i>	81
<i>Cochleates</i>	82
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	82
<i>DNA nanoparticles as nonviral vectors</i>	82
<i>Gelatin nanoparticles for gene delivery</i>	82
<i>Lipid nanoparticles for nucleic acid delivery</i>	83
<i>Lipid nanoparticles for delivery of genome-editing proteins</i>	83
<i>Nanoparticles as nonviral vectors for gene therapy</i>	83
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	84
<i>Nanobiotistics for nucleic acid delivery</i>	84
<i>Nonionic polymeric micelles for oral gene delivery</i>	85
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	85
<i>Virus-like particles as nonviral vector</i>	85
Receptor-mediated endocytosis	85
Artificial viral vectors.....	87
Directed evolution of AAV to create efficient gene delivery vectors	87
Bacterial ghosts as DNA delivery systems	87
Bacteria plus nanoparticles for gene delivery into cells.....	88
Chromosome-based vectors for gene therapy.....	89
<i>Mammalian artificial chromosomes (MACs)</i>	89
<i>Human artificial chromosomes (HACs)</i>	90
<i>ΦC31 integrase system</i>	90
Companies using nonviral vectors	90
Concluding remarks about vectors	91
Cell-mediated gene therapy	92
Fibroblasts	93
Skeletal muscle cells	93
Vascular smooth muscle cells	94
Keratinocytes	94
Hepatocytes	94
Lymphocytes.....	95
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	95
Implantation of microencapsulated genetically modified cells	95
Stem cell gene therapy.....	96
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	96
<i>Improving delivery of genes to stem cells</i>	97
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	97
<i>Use of mesenchymal stem cells for gene therapy</i>	97

<i>Microporation for transfection of MSCs</i>	97
<i>In utero gene therapy using stem cells</i>	97
<i>Gene delivery to stem cells by artificial chromosome expression</i>	98
<i>Linker based sperm-mediated gene transfer technology</i>	98
<i>Combination of gene therapy with therapeutic cloning</i>	98
<i>Expansion of transduced HSCs in vivo</i>	99
<i>The future of hematopoietic stem cell gene therapy</i>	99
Role of genetically modified bacteria in gene therapy.....	99
Routes of administration for gene therapy	100
Direct injection of naked DNA.....	100
Intramuscular injection.....	101
Intravenous DNA injection.....	101
Intraarterial delivery.....	101
Companies with gene delivery devices/technologies.....	101
Targeted gene therapy	103
Targeted integration.....	103
Bacteriophage integrase system for site-specific gene delivery.....	103
Controlled-release delivery of DNA.....	104
Controlled gene therapy	104
Controlled delivery of genetic material.....	104
Controlled induction of gene expression.....	105
Drug-inducible systems for control of gene expression.....	105
Timed activation of gene therapy by a circuit based on signaling network.....	106
Small molecules for post-transcriptional regulation of gene expression.....	106
Engineered zinc finger DNA binding proteins for gene correction.....	107
Light Activated Gene Therapy.....	107
Spatial control of gene expression via local hyperthermia.....	107
Companies with regulated /targeted gene therapy.....	107
Gene marking	109
Germline gene therapy	109
Potential applications of human germline genome modification.....	109
Pros and cons of human germline genome modification.....	110
Role of gene transfer in antibody therapy	111
Genetically engineered vaccines	111
DNA vaccines.....	111
<i>DNA inoculation technology</i>	112
<i>Methods for enhancing the potency of DNA vaccines</i>	112
<i>Advantages of DNA vaccines</i>	113
Vaccine vectors.....	113
Challenges and limitations of genetically engineered vaccines.....	114
RNA vaccines.....	115
<i>Nonviral delivery of self-amplifying RNA vaccine</i>	115
Vaccines based on reverse genetics.....	115
Technologies for gene suppression	115
Antisense oligonucleotides.....	115
Transcription factor decoys.....	116
Aptamers.....	117
Ribozymes.....	117
Peptide nucleic acid.....	117
<i>Intracellular delivery of PNAs</i>	118
Locked nucleic acid.....	118
<i>Zorro-LNA</i>	118
Gene silencing.....	119
Post-transcriptional gene silencing.....	119
Definitions and terminology of RNAi.....	119
RNAi mechanisms.....	119
Inhibition of gene expression by antigene RNA.....	120
RNAi gene therapy.....	121
microRNA gene therapy.....	121
Viral vectors for RNAi and miRNA gene therapy.....	121
Application of molecular diagnostic methods in gene therapy	122
Use of PCR to study biodistribution of gene therapy vector.....	123
PCR for verification of the transcription of DNA.....	123
In situ PCR for direct quantification of gene transfer into cells.....	123
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	124
Confirmation of viral vector integration.....	124
Monitoring of gene expression.....	124
<i>Monitoring of gene expression by green fluorescent protein</i>	124
<i>Monitoring in vivo gene expression by molecular imaging</i>	125
<i>Advantages of gene therapy compared with protein therapy</i>	125
Formulation, transport and storage of materials for gene therapy	125

3. Clinical Applications of Gene Therapy	127
Introduction	127
Aging research.....	127
Bone and joint disorders.....	127
Bone fractures.....	127
Gene therapy for intervertebral disc degeneration.....	128
Spinal fusion	129
Osteogenesis imperfecta	129
Rheumatoid arthritis.....	130
<i>Local or systemic treatment</i>	<i>130</i>
<i>In vivo or ex vivo gene therapy of RA.....</i>	<i>130</i>
<i>Clinical trials of gene therapy for rheumatoid arthritis.....</i>	<i>131</i>
Gene therapy for osteoarthritis.....	132
Sports injuries.....	134
<i>Repair of articular cartilage defects</i>	<i>134</i>
Regeneration and replacement of bone by gene therapy	135
Bacterial infections	135
Antisense approach to bacterial infections	136
Dentistry.....	136
Tissue engineering in dental implant defects	136
Endocrine and metabolic disorders	137
Introduction	137
Gene therapy of obesity.....	137
<i>AAV vector-mediated delivery of GDNF for obesity</i>	<i>137</i>
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes.....</i>	<i>137</i>
<i>Viral vector-mediated leptin gene therapy.....</i>	<i>138</i>
Diabetes mellitus	138
Methods of gene therapy of diabetes mellitus	139
<i>Viral vector-mediated gene transfer in diabetes</i>	<i>140</i>
<i>Gene delivery with ultrasonic microbubble destruction technology.....</i>	<i>140</i>
<i>Genetically engineered cells for diabetes mellitus.....</i>	<i>141</i>
<i>Genetically altered liver cells.....</i>	<i>141</i>
<i>Genetically modified stem cells.....</i>	<i>141</i>
<i>Genetically engineered dendritic cells</i>	<i>142</i>
<i>Glucokinase and insulin co-expression</i>	<i>142</i>
<i>Leptin gene therapy</i>	<i>142</i>
<i>Concluding remarks about cell and gene therapy of diabetes</i>	<i>142</i>
Gene therapy of growth-hormone deficiency	143
Gastrointestinal disorders.....	144
Introduction	144
Methods of gene transfer to the gastrointestinal tract.....	144
<i>Direct delivery of genes</i>	<i>145</i>
<i>Naked plasmid DNA into the submucosa</i>	<i>145</i>
<i>Viral vectors.....</i>	<i>145</i>
<i>Receptor-mediated endocytosis</i>	<i>145</i>
Indications for gastrointestinal gene therapy	145
<i>Gene therapy for inflammatory disorders of the bowel.....</i>	<i>146</i>
Gene transfer to the salivary glands.....	147
<i>Potential clinical applications of salivary gene therapy</i>	<i>147</i>
Hematology	148
Hemophilias	148
<i>Gene therapy of hemophilia</i>	<i>148</i>
<i>Hemophilia A.....</i>	<i>149</i>
<i>Hemophilia B.....</i>	<i>150</i>
<i>Concluding remarks about gene therapy of hemophilias.....</i>	<i>151</i>
Hemoglobinopathies.....	151
<i>Gene therapy for β-thalassemia.....</i>	<i>152</i>
<i>Gene therapy for sickle cell disease.....</i>	<i>153</i>
<i>Gene therapy and RNAi for SCD based on stem cells</i>	<i>153</i>
<i>Gene editing in sickle cell disease</i>	<i>154</i>
<i>Gene editing using ZFN as treatment for both SCD and β-thalassemia.....</i>	<i>154</i>
<i>Gene editing using CRISPR-Cas9 for both SCD and β-thalassemia.....</i>	<i>155</i>
<i>Gene therapy of Fanconi's anemia.....</i>	<i>155</i>
Acquired hematopoietic disorders.....	155
<i>Chronic acquired anemias</i>	<i>155</i>
<i>Neutropenia</i>	<i>156</i>
<i>Thrombocytopenia</i>	<i>157</i>
Concluding remarks about gene therapy of hemoglobinopathies	157
Companies involved in gene therapy of hematological disorders	158
In utero/fetal gene therapy.....	158
Fetal gene transfer techniques.....	159

Animal models of fetal gene therapy	159
Potential applications of fetal gene therapy	160
<i>Fetal gene therapy for cystic fibrosis</i>	160
<i>Fetal intestinal gene therapy</i>	161
<i>Gene therapy for fetal growth restriction</i>	161
Hearing disorders	161
Potential of gene therapy	162
Vectors for gene therapy of hearing disorders.....	162
Auditory hair cell replacement and hearing improvement by gene therapy	163
Kidney diseases	163
End-stage renal disease.....	163
Methods of gene delivery to the kidney	164
<i>Gene transfer into kidney by adenoviral vectors</i>	164
<i>Non-viral gene transfer to the kidneys</i>	164
<i>Gene transfer into the glomerulus by HVJ-liposome</i>	164
<i>Bone marrow stem cells for renal disease</i>	165
<i>Mesangial cell therapy</i>	165
<i>Liposome-mediated gene transfer into the tubules</i>	166
<i>Gene transfer to tubules with cationic polymer polyethylenimine</i>	166
Gene therapy in animal experimental models of renal disease	166
Genetic manipulations of the embryonic kidney	167
Antisense intervention in glomerulonephritis	167
Gene therapy for renal fibrosis	167
Use of genetically engineered cells for uremia due to renal failure.....	168
Concluding remarks	168
Liver disorders.....	168
Techniques of gene delivery to liver	169
<i>Direct injection of DNA into liver</i>	169
<i>Local gene delivery by isolated organ perfusion</i>	170
<i>Liposome-mediated direct gene transfer</i>	170
<i>Retroviral vector for gene transfer to liver</i>	170
<i>Adenoviral vectors for gene transfer to liver</i>	170
<i>Receptor-mediated approach</i>	171
Cell therapy for liver disorders.....	171
<i>Transplantation of genetically modified hepatocytes</i>	171
<i>Genetically modified hematopoietic stem cells</i>	171
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	172
Gene therapy of genetic diseases affecting the liver	172
<i>Crigler-Najjar syndrome</i>	172
<i>Hereditary tyrosinemia type I (HT1)</i>	172
<i>Hereditary tyrosinemia type 3</i>	173
Gene therapy of acquired diseases affecting the liver	173
<i>Cirrhosis of liver</i>	173
Ophthalmic disorders.....	174
Introduction to gene therapy of ophthalmic disorders	174
Methods of gene therapy for ophthalmic disorders	175
<i>Delivery of gene therapy by intravitreal injection</i>	176
<i>DNA nanoparticles for nonviral gene transfer to the eye</i>	176
<i>Optogenetic gene therapy for blindness due to retinal degeneration</i>	176
Age-related macular degeneration	177
Inherited disorders of optic nerve affecting vision	178
<i>Leber hereditary optic neuropathy</i>	179
Inherited retinal degenerations.....	179
<i>Choroideremia</i>	180
<i>Leber congenital amaurosis</i>	181
<i>Retinitis pigmentosa</i>	183
<i>Stargardt disease</i>	184
Other inherited disorders affecting vision	184
<i>Color blindness</i>	184
<i>Usher syndrome</i>	185
<i>X-linked retinoschisis</i>	186
Diabetic retinopathy	187
Future prospects of gene therapy of inherited retinal degenerations	187
<i>Combining cell and gene therapies for retinal disorders</i>	187
Prevention of complications associated with eye surgery	188
<i>Prevention of proliferative retinopathy by gene therapy</i>	188
<i>Posterior capsule opacification after cataract surgery</i>	188
Autoimmune uveitis	188
Retinal ischemic injury.....	189
Corneal disorders.....	189
Glaucoma	189

Corneal scarring	190
Companies developing gene therapy for eye disorders	190
Organ transplantation.....	191
Introduction	191
DNA vaccines for transplantation	191
Gene therapy for prolonging allograft survival	191
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i>	191
Gene therapy in lung transplantation.....	192
Role of gene therapy in liver transplantation	192
Gene therapy in kidney transplantation.....	193
Veto cells and transplant tolerance.....	193
Pulmonary disorders.....	194
Techniques of gene delivery to the lungs	194
<i>Adenoviral vectors</i>	194
<i>Nonviral vectors</i>	195
<i>Aerosolization as an aid to gene transfer to lungs.</i>	195
Cystic fibrosis.....	196
<i>Genetics and clinical features</i>	196
<i>Gene therapy for CF</i>	196
<i>CFTR gene transfer in CF</i>	196
<i>Concluding remarks about gene therapy of CF</i>	198
Miscellaneous pulmonary disorders	198
<i>Gene therapy for pulmonary arterial hypertension</i>	198
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	199
<i>Gene therapy of emphysema due to α1-antitrypsin deficiency</i>	199
<i>Gene therapy for asthma</i>	200
<i>Gene therapy for adult respiratory distress syndrome</i>	200
<i>Gene therapy for lung injury</i>	201
<i>Gene therapy for bronchopulmonary dysplasia</i>	201
Concluding remarks about gene therapy of lungs.....	201
Companies involved in pulmonary gene therapy	202
Skin and soft tissue disorders.....	203
Gene transfer to the skin	203
<i>Electroporation for transdermal delivery of plasmid DNA</i>	203
<i>Electroporation for transdermal delivery of DNA vaccines</i>	204
<i>Liposomes for transdermal gene delivery</i>	204
<i>Ultrasound and topical gene therapy</i>	204
Gene therapy in skin disorders	204
<i>Gene therapy of hair loss</i>	205
<i>Gene therapy for epidermolysis bullosa</i>	205
<i>Gene therapy for xeroderma pigmentosa</i>	206
<i>Gene therapy for lamellar ichthyosis</i>	206
<i>Gene therapy for epidermolysis bullosa</i>	207
Gene transfer techniques for wound healing	207
Urogenital disorders	208
Gene therapy for urinary tract dysfunction	208
Gene therapy for erectile dysfunction	208
<i>NOS gene transfer for erectile dysfunction</i>	208
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	209
<i>Gene therapy for erectile dysfunction due to nerve injury</i>	209
<i>Concluding remarks on gene therapy for erectile dysfunction</i>	209
Veterinary gene therapy	210
Gene therapy for mucopolysaccharidosis VII in dogs	210
Gene therapy to increase disease resistance.....	210
Gene therapy for infections	211
Gene therapy for chronic anemia	211
Gene therapy for endocrine disorders	212
Gene therapy for arthritis.....	212
Cancer gene therapy	212
<i>Brain tumors in cats and dogs</i>	213
<i>Breast cancer in dogs</i>	213
<i>Canine hemangiosarcoma</i>	214
<i>Canine melanoma</i>	214
<i>Canine soft tissue sarcoma</i>	214
Melanoma in horses	215
4. Gene Therapy of Genetic Disorders.....	216
Introduction	216
Primary immunodeficiency disorders.....	217
Severe combined immune deficiency	218
Chronic granulomatous disease	221

Wiskott-Aldrich syndrome	221
Purine nucleoside phosphorylase deficiency	222
Major histocompatibility class II deficiency	222
Future prospects of gene therapy of inherited immunodeficiencies	223
Metabolic disorders.....	223
Alpha1-antitrypsin deficiency.....	224
<i>AAV mediated gene therapy for α1-antitrypsin deficiency.....</i>	<i>224</i>
<i>iPSCs for targeted gene correction of α1-antitrypsin deficiency.....</i>	<i>225</i>
Adrenoleukodystrophy	226
Canavan disease.....	227
Lesch-Nyhan syndrome	228
Lipoprotein lipase deficiency.....	228
<i>Alipogene tiparvovec.....</i>	<i>228</i>
Ornithine transcarbamylase deficiency.....	229
<i>Gene therapy for OTCD.....</i>	<i>229</i>
<i>AAV-mediated gene editing for OTCD using CRISPR-Cas9.....</i>	<i>230</i>
Phenylketonuria.....	230
Porphyrias	230
Tetrahydrobiopterin deficiency.....	231
Lysosomal storage disorders.	232
Batten disease.....	233
Fabry's disease.....	233
Farber's disease.....	234
Gaucher disease	234
<i>Animals models of Gaucher's disease.....</i>	<i>234</i>
<i>Gene therapy of Gaucher's disease.....</i>	<i>235</i>
Hunter syndrome.....	235
Krabbe's disease.....	236
Metachromatic leukodystrophy	237
Mucopolysaccharidosis type 1 (Hurler syndrome).....	237
Niemann-Pick type A disease.....	238
Pompe disease	238
Sanfilippo A syndrome.....	239
Sly syndrome	239
Tay-Sachs disease	240
Future prospects of gene therapy of lysosomal storage disorders	240
Trinucleotide repeat disorders.....	241
Muscular dystrophies.....	241
Duchenne muscular dystrophy (DMD).....	241
<i>Animal models for gene therapy of DMD.....</i>	<i>242</i>
<i>Antisense approaches to DMD.....</i>	<i>242</i>
<i>Exon-skipping for DMD.....</i>	<i>242</i>
<i>Galgt2 gene therapy.....</i>	<i>243</i>
<i>Liposome-mediated gene transfer.....</i>	<i>244</i>
<i>Microdystrophin gene therapy.....</i>	<i>244</i>
<i>Myoblast-based gene transfer in DMD.....</i>	<i>244</i>
<i>Plasmid-mediated gene therapy.....</i>	<i>245</i>
<i>Purinoreceptor P2RX7 ablation.....</i>	<i>245</i>
<i>Post-transcriptional modulation of gene expression in DMD.....</i>	<i>245</i>
<i>Repair/Editing of dystrophin gene.....</i>	<i>246</i>
<i>Routes of administration of gene therapy in DMD.....</i>	<i>248</i>
<i>Types of dystrophin constructs.....</i>	<i>249</i>
<i>Viral vectors for DMD.....</i>	<i>249</i>
<i>Conclusions and future of gene therapy of DMD.....</i>	<i>250</i>
Limb-girdle muscular dystrophy.....	251
Myotonic dystrophy	251
Spinal muscular atrophy	252
<i>Gene therapy for SMA.....</i>	<i>252</i>
<i>Antisense therapy of SMA.....</i>	<i>252</i>
X-linked myotubular myopathy (XLMTM).....	253
Hereditary neuropathies.....	253
Charcot-Marie-Tooth disease	253
Hereditary axonal neuropathies of the peripheral nerves.....	254
Gene therapy of mitochondrial disorders.....	254
Techniques for mitochondrial replacement therapy.....	255
Status of mitochondrial replacement and transfer therapies	256
Companies involved in gene therapy of genetic disorders	257
5. Gene Therapy of Cancer.....	258
Strategies for cancer gene therapy.....	258
Direct gene delivery to the tumor	259

Injection into tumor	259
<i>Direct injection of adenoviral vectors</i>	259
<i>Direct injection of a plasmid DNA-liposome complex</i>	260
<i>A polymer approach to local gene therapy for cancer</i>	260
Electroporation for cancer gene therapy	260
Control of gene expression in tumor by local heat	261
Radiation-guided gene therapy of cancer	261
Radioprotective gene therapy	261
Nanoparticles to facilitate combination of hyperthermia and gene therapy	262
Cell-based cancer gene therapy	262
Adoptive cell therapy	262
Cytokine gene therapy	263
Genetic modification of human hematopoietic stem cells	266
Immunogene therapy	266
Cancer vaccines	267
Genetically modified cancer cell vaccines	267
<i>GVAX cancer vaccines</i>	267
<i>Genetically modified dendritic cells</i>	268
Nucleic acid-based cancer vaccines	268
<i>DNA cancer vaccines</i>	268
<i>RNA vaccines</i>	268
Viral vector-based cancer vaccines	269
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	269
Future of cancer vaccines	270
Companies involved in nucleic acid-based cancer vaccines	270
Monoclonal antibody gene transfer for cancer	271
Transfer and expression of intracellular adhesion-1 molecules	271
Other gene therapy techniques for immunotherapy of cancer	271
Chemokines	272
CRISPR for immunogene therapy	272
Engineered viruses as anticancer immunotherapy vectors	273
Fas (Apo-1)	273
Major Histocompatibility Complex (MHC) Class I	273
IGF (Insulin-Like Growth Factor)	274
Inhibition of immunosuppressive function in cancer	274
Delivery of toxic genes to tumor cells for eradication	274
Gene-directed enzyme prodrug therapy	274
Combination of gene therapy with radiotherapy	275
Correction of genetic defects in cancer cells	275
Targeted gene therapy for cancer	276
Antiangiogenic therapy for cancer	276
Bacteria as novel anticancer gene vectors	277
Cancer-specific gene expression	277
Cancer-specific transcription	277
Delivery of retroviral particles hitchhiking on T cells	278
Electrogene and electrochemotherapy	278
Epidermal growth factor-mediated DNA delivery	278
Gene-based targeted drug delivery to tumors	279
Gene expression in hypoxic tumor cells	279
Genetically modified T cells for targeting tumors	280
<i>Chimeric antigen receptor T cells</i>	280
Genetically engineered stem cells for targeting tumors	283
Hematopoietic stem cells for targeted cancer gene therapy	283
Immunolipoplex for delivery of p53 gene	284
Nanomagnets for targeted cell-based cancer gene therapy	284
Nanoparticles for targeted site-specific delivery of anticancer genes	285
Targeted cancer therapy using a dendrimer-based synthetic vector	285
Tumor-targeted gene therapy by receptor-mediated endocytosis	285
Virus-mediated oncolysis	286
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	286
<i>Monitoring of viral-mediated oncolysis by PET</i>	286
<i>Oncolytic adenoviruses</i>	287
<i>Oncolytic HSV</i>	288
<i>Oncolytic measles viruses</i>	288
<i>Oncolytic vaccinia virus</i>	289
<i>Oncolytic vesicular stomatitis virus</i>	289
<i>Targeted cancer treatments based on oncolytic viruses</i>	289
<i>Concluding remarks on oncolytic gene therapy</i>	290
<i>Companies developing oncolytic viruses</i>	290
Apoptotic approach to improve cancer gene therapy	291
Tumor suppressor gene therapy	292

P53 gene therapy.....	292
BRIT1 gene therapy	292
Nitric oxide-based cancer gene therapy.....	292
Anticancer effect of nitric oxide synthase	292
Gene therapy for radiosensitization of cancer	293
Gene therapy of cancer of selected organs	293
Gene therapy for bladder cancer	293
Gene therapy for glioblastoma multiforme.	294
<i>Adenoviral vectors for treatment of brain tumors</i>	295
<i>Antiangiogenic gene therapy</i>	295
<i>Autophagy induced by conditionally replicating adenoviruses</i>	296
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	296
<i>Cerepro® (sitimagene ceradenovec)</i>	297
<i>Gene therapy targeting hepatocyte growth factor</i>	297
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	297
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	297
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	298
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i>	298
<i>RNAi gene therapy of brain cancer</i>	298
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	299
<i>Viral oncolysis of glioblastoma multiforme</i>	299
Gene therapy for breast cancer.....	301
<i>Gene vaccine for breast cancer</i>	301
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	302
Gene Therapy for ovarian cancer	302
Gene therapy for malignant melanoma	303
<i>Immunogene therapy</i>	304
<i>Nonviral immunogene therapy for malignant melanoma</i>	305
<i>Oncogene targeted therapy</i>	305
<i>Targeted gene therapy for malignant melanoma</i>	305
Gene therapy of lung cancer.....	305
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i>	306
<i>Aerosol gene delivery for lung cancer</i>	306
Gene therapy for cancer of prostate	306
<i>Experimental studies</i>	306
<i>Nanoparticle-based gene therapy for prostate cancer</i>	307
<i>Tumor suppressor gene therapy in prostate cancer</i>	307
<i>Vaccines for prostate cancer</i>	307
<i>Viral oncolysis for prostate cancer</i>	308
<i>Clinical trials of gene therapy for prostate cancer</i>	308
Gene therapy of head and neck cancer	309
<i>Adenoviral vector based P53 gene therapy</i>	309
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i>	309
Gene therapy of pancreatic tumors	309
<i>Pancreatic neuroendocrine tumors</i>	309
<i>Pancreatic ductal adenocarcinoma</i>	310
<i>Correction of altered genes</i>	310
<i>Targeted gene therapy</i>	311
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i>	311
<i>Targeted Expression of BikDD gene</i>	311
<i>Viral oncolysis in pancreatic cancer</i>	312
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	312
Gene therapy of renal cancer.....	312
<i>Viral oncolytic therapy for renal cancer</i>	312
Gene therapy of hematological malignancies	312
<i>Genetically engineered T lymphocytes</i>	313
Cancer gene therapy companies	313
6. Gene Therapy of Neurological Disorders	317
Indications	317
Gene transfer techniques for the nervous system.....	318
Methods of gene transfer to the nervous system.....	318
Ideal vector for gene therapy of neurological disorders	318
Promoters of gene transfer.....	318
Lentivirus-mediated gene transfer to the CNS	319
AAV vector mediated gene therapy for neurogenetic disorders.....	319
Gene transfer to the CNS using recombinant SV40-derived vectors	320
Routes of delivery of genes to the CNS	320
<i>Direct injection into CNS</i>	320
<i>Introduction of the genes into cerebral circulation</i>	321
<i>Introduction of genes into cerebrospinal fluid</i>	321

<i>Intravenous administration of vectors</i>	322
Delivery of gene therapy to the peripheral nervous system	322
Cell-mediated gene therapy of neurological disorders	322
<i>Neuronal cells</i>	322
<i>Neural stem cells and progenitor cells</i>	322
<i>Astrocytes</i>	323
<i>Cerebral endothelial cells</i>	323
<i>Implantation of genetically modified encapsulated cells into the brain</i>	323
Gene transfer for neuromodulation.....	323
Gene therapy of neurodegenerative disorders	324
Gene therapy for Parkinson disease.....	324
Rationale	325
<i>Techniques of gene therapy for PD</i>	325
<i>Augmenting CNS glucocerebrosidase activity</i>	329
<i>Delivery of neurotrophic factors by gene therapy</i>	329
<i>Delivery of parkin gene</i>	330
<i>Introduction of functional genes into the brain of patients with PD</i>	330
<i>Nanoparticle-based gene therapy for PD</i>	330
<i>Mitochondrial gene therapy for PD</i>	330
<i>RNAi approach to PD</i>	331
<i>Prospects of gene therapy for PD</i>	331
<i>Concluding remarks about gene therapy of PD</i>	332
<i>Companies developing gene therapy for PD</i>	332
Gene therapy for Alzheimer disease	333
Rationale	333
<i>NGF gene therapy for AD</i>	333
<i>FGF2 gene transfer in AD</i>	334
<i>Nepriylsin gene therapy</i>	335
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	335
<i>Viral gene transfer of APPsα for rescuing synaptic failure in AD</i>	335
<i>Gene vaccination</i>	336
<i>Combination of gene therapy with other treatments for AD</i>	336
Gene therapy of Huntington disease.....	336
<i>Encapsulated genetically engineered cellular implants</i>	336
<i>Viral vector mediated administration of neurotrophic factors</i>	337
<i>RNAi gene therapy</i>	337
Gene therapy of amyotrophic lateral sclerosis.....	337
Rationale	337
<i>Technique of gene therapy of ALS</i>	337
<i>Other approaches to gene therapy of ALS</i>	339
Gene therapy of cerebrovascular diseases	339
Preclinical research in gene therapy for cerebrovascular disease	339
Animal models of stroke relevant to gene therapy.....	339
<i>Transgenic mice as models for stroke</i>	340
<i>Animal models for gene therapy of arteriovenous malformations</i>	340
Gene transfer to cerebral blood vessels	340
Gene therapy for vasospasm following subarachnoid hemorrhage	341
<i>NOS gene therapy for cerebral vasospasm</i>	342
Gene therapy for stroke.....	343
<i>Gene therapy for stroke using neurotrophic factors</i>	344
<i>Gene therapy of strokes with a genetic component</i>	344
<i>Gene therapy for intracranial aneurysms</i>	344
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	345
Concluding remarks about gene therapy for stroke.....	345
Gene therapy of injuries to the nervous system.....	345
Traumatic brain injury	345
Spinal cord injury.....	346
Peripheral nerve injuries	347
Gene therapy of epilepsy	347
Gene therapy for control of seizures.....	347
Gene therapy for neuroprotection in epilepsy	348
Gene therapy for genetic forms of epilepsy	349
Gene therapy for multiple sclerosis	349
Gene therapy for impairment of special senses	350
Gene therapy for hearing loss.....	350
Gene therapy for olfactory impairment	351
Gene therapy for relief of pain	351
Rationale of gene therapy for pain	351
Vectors for gene therapy of pain	351
Methods of gene delivery for pain	352
<i>Endogenous analgesic production for cranial neuralgias</i>	352

Gene delivery by intrathecal route	353
Gene transfer for delivery of analgesics to the spinal nerve roots	353
Gene therapy of peripheral neuropathic pain	354
Gene transfer by injections into the brain substance.....	355
Targets for gene therapy of pain	355
Zinc finger DNA-binding protein therapeutic for chronic pain	355
Gene therapy for producing enkephalin to block pain signals	356
Targeting nuclear factor- κ B	356
Gene therapy targeted to neuroimmune component of chronic pain	357
Potential applications of gene therapy for management of pain	357
Concluding remarks on gene therapy for pain.....	358
Gene therapy for psychiatric disorders	359
Gene therapy for depression	359
Gene therapy for enhancing cognition after stress.....	359
Gene therapy against fear disorders	360
Companies involved in gene therapy of neurological disorders.....	360

7. Gene Therapy of Cardiovascular Disorders	361
Introduction	361
Techniques of gene transfer to the cardiovascular system	361
Direct plasmid injection into the myocardium	362
Catheter-based systems for vector delivery.....	362
Ultrasound microbubbles for cardiovascular gene delivery	363
Vectors for cardiovascular gene therapy	363
AAV vectors for therapeutic delivery to the heart	363
Adenoviral vectors for cardiovascular diseases.....	364
Molecular cardiac surgery with recirculating delivery of AAV vectors	364
Plasmid DNA-based delivery in cardiovascular disorders.....	364
Gene therapy for counteracting hypoxia in myocardial ischemia.....	364
Therapeutic angiogenesis vs vascular growth factor therapy.....	365
Gene painting for delivery of targeted gene therapy to the heart	365
Gene delivery to vascular endothelium	366
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	366
Vascular stents for gene delivery	367
Gene therapy for genetic cardiovascular disorders	367
Genetic disorders predisposing to atherosclerosis.....	367
Familial hypercholesterolemia.....	368
Apolipoprotein E deficiency.....	369
Hypertension.....	370
Genetic factors for myocardial infarction	370
Acquired cardiovascular diseases	371
Coronary artery disease with angina pectoris.....	371
Ad5FGF-4.....	371
Gene therapy for improving long-term CABG patency rates.....	372
Ischemic heart disease with myocardial infarction	372
Gene therapy and angiogenesis in ischemic heart disease	373
Induction of angiogenesis in myocardium by HEXIM1 re-expression	373
Myocardial repair with IGF-1 therapy.....	374
Metalloproteinase-2 inhibitor gene therapy.....	374
miRNA gene therapy for ischemic heart disease	375
Congestive heart failure.....	375
Rationale of gene therapy in CHF	375
AAV-mediated gene transfer for CHF	376
AngioCell gene therapy for CHF	376
β -ARKct gene therapy.....	376
Elevating cardiac dATP by gene therapy to improve cardiac function.....	377
Elevating cardiac adenyl cyclase type 6 to improve cardiac function.....	377
Intracoronary adenovirus-mediated gene therapy for CHF.....	378
nNOS gene transfer in CHF.....	379
Cardiomyopathies	379
Cardiac conduction disturbances	379
Gene transfer approaches for biological pacemakers.....	379
Genetically engineered biological pacemakers.....	380
Gene therapy and heart transplantation.....	381
Hyperlipidemia and hypercholesterolemia	381
Antisense approach to hypertriglyceridemia.....	381
Cholesterol reduction by genetic engineering of PCSK9 gene	382
Inactivating variants in ANGPTL4 for lowering circulating triglycerides	382
Peripheral arterial disease	382
Incidence and clinical features	382
Current management	383

Gene therapy for peripheral arterial disease	383
<i>Angiogenesis by gene therapy</i>	383
<i>HIF-1α gene therapy for peripheral arterial disease</i>	383
<i>HGF gene therapy for peripheral arterial disease</i>	384
Prevention of restenosis after angioplasty	384
<i>Antisense approaches</i>	385
<i>Gene therapy to prevent restenosis after angioplasty</i>	385
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	387
<i>miRNA-based gene therapy for restenosis</i>	387
<i>NOS gene therapy for restenosis</i>	387
<i>Techniques of gene therapy for restenosis</i>	388
Maintaining vascular patency after surgery	388
Companies involved in gene therapy of cardiovascular diseases	389
Future prospects of gene therapy of cardiovascular disorders	390
8. Gene therapy of viral infections	391
Introduction	391
Acquired Immunodeficiency Syndrome (AIDS)	391
Current management of AIDS	391
Gene therapy strategies in HIV/AIDS	392
<i>HIV/AIDS vaccines</i>	392
<i>Insertion of protective genes into target cells</i>	393
Cell/gene therapies for HIV/AIDS	394
<i>Transplantation of genetically modified T cells</i>	394
<i>Transplantation of genetically modified hematopoietic cells</i>	395
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	396
Inhibition of HIV-1 replication by lentiviral vectors	396
<i>VRX496-T</i>	396
Intracellular immunization	397
Engineered cellular proteins such as soluble CD4s	397
Intracellular antibodies	397
Anti-rev single chain antibody fragment	398
Use of genes to chemosensitize HIV-1 infected cells	398
Autocrine interferon (INF)- β production by somatic cell gene therapy	398
Antisense approaches to AIDS	398
<i>RNA decoys</i>	398
<i>Antisense oligodeoxynucleotides</i>	399
<i>RNA decoys</i>	399
<i>Ribozymes</i>	399
RNAi applications in HIV/AIDS	400
<i>siRNA-directed inhibition of HIV-1 infection</i>	400
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	401
<i>Bispecific siRNA constructs</i>	401
<i>Targeting CXCR4 with siRNAs</i>	401
<i>Targeting CCR5 with siRNAs</i>	402
Companies involved in developing gene therapy for HIV/AIDS	402
Conclusions regarding gene therapy of HIV/AIDS	403
Genetic vaccines for other viral infections	404
Cytomegalic virus infections	404
Viral hepatitis	404
<i>Vaccine for hepatitis B</i>	405
<i>Vaccine for hepatitis C</i>	405
<i>Gene therapy for hepatitis C</i>	405
Vaccine for herpes simplex virus	405
DNA vaccine against rabies	406
DNA vaccine for Ebola	406
Vaccines for avian influenza	407
<i>Future prospects of DNA vaccines for avian influenza</i>	408
<i>Human trial of a DNA vaccine for avian influenza</i>	408
Companies developing genetic vaccines for infections other than AIDS	409
9. Research, Development and Future of Gene Therapy	411
Basic research in gene therapy	411
R & D in gene therapy	411
Animal models of human diseases for gene therapy research	412
<i>Lentiviral transgenesis</i>	412
Financing research and development	412
Role of the NIH in gene therapy research	412
National Gene Vector Laboratories	412
Funding of gene therapy research in Europe	413
<i>Gene therapy funding in Horizon 2020 of European Commission</i>	413

Financing by the industry	414
Clinical trials in gene therapy	414
Clinical trials worldwide	414
<i>Clinical trials in cancer gene therapy</i>	<i>415</i>
<i>Trials of gene therapy for neurological disorders</i>	<i>415</i>
<i>Clinical trials for genetic disorders</i>	<i>415</i>
<i>Clinical trials in cardiovascular gene therapy</i>	<i>415</i>
<i>Clinical trials for infectious diseases</i>	<i>415</i>
<i>Gene therapy for other disorders</i>	<i>415</i>
Clinical trials in the US	416
Vectors used in gene therapy clinical trials	416
<i>Vector analytics for clinical trials using rAAV vectors</i>	<i>417</i>
Future prospects for the gene therapy	417
How to improve gene therapy	418
International Gene Therapy Consortium	418
Future opportunities and challenges for gene therapy	420
Promising areas of application of gene therapy	420
<i>Neurological disorders</i>	<i>421</i>
<i>Gene therapy of cardiovascular disorders</i>	<i>421</i>
<i>Cancer gene therapy</i>	<i>422</i>
Personalized gene therapy	423
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy	425
Regulation of gene therapy in the United States	425
US Federal guidelines for research involving recombinant DNA molecules	425
Regulation of gene therapy in US	425
Implantation of genetically manipulated cells	425
<i>Modification of oocytes for use in IVF</i>	<i>426</i>
Clinical trials in gene therapy	426
Cell and gene therapy INDs placed on hold by the FDA	426
Regulation of gene therapy in Europe	427
European Union	427
Regulation of gene therapy in Germany	428
<i>Preclinical research</i>	<i>428</i>
<i>Clinical Trials</i>	<i>429</i>
Marketing authorization	430
Regulation of gene therapy in the United Kingdom	430
Regulation of gene therapy in France	431
Regulation of gene therapy in Italy	431
Regulation of gene therapy in the Netherlands	432
Gene therapy regulation in Switzerland	433
Regulation of gene therapy in Australia	433
Regulation of gene therapy in Japan	434
Regulation of gene therapy in China	434
Safety issues of gene transfer	435
Adverse effects of retroviral vectors	435
<i>Insertional mutagenesis</i>	<i>435</i>
Adverse effects of HSV vectors	436
<i>Neurotoxicity of HSV vectors</i>	<i>436</i>
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	<i>436</i>
Adverse effects of adenoviral vectors	437
<i>Inflammatory effects of adenoviruses in lungs</i>	<i>437</i>
<i>Inflammatory effects involving the liver</i>	<i>437</i>
<i>Induction of immune response by adenoviral vectors</i>	<i>438</i>
<i>Impairment of adrenocortical steroidogenesis</i>	<i>438</i>
<i>Adverse effects of AAV vectors</i>	<i>438</i>
Toxicity associated with cationic lipid-mediated gene transfer	439
Toxicity of lipopolysaccharides	439
Potential side effects of RNAi gene therapy	439
Role of molecular diagnostics in safety of gene therapy	440
Quality control of vectors	440
<i>Testing for retroviruses</i>	<i>440</i>
<i>Adenoviral vectors</i>	<i>440</i>
<i>Replication competent viruses</i>	<i>441</i>
Genetic characteristics of viral vectors	441
Concluding remarks about safety of viral vectors	441
Ethical aspects of gene therapy	442
The lay consumer's view of somatic gene therapy ethics	442
Ethical aspects of clinical trials	443
Regulatory and ethical issues for in utero gene therapy	443
Ethical aspects of germline gene therapy	443

Ethical aspects of mitochondrial replacement therapy	444
Ethical aspects of gene editing	444
Germline gene therapy for genetic enhancement	446
Athletic enhancement by genetic engineering	447
<i>Gene doping in sports</i>	447
<i>Gene transfer methods used for enhancing physical performance</i>	447
<i>Adverse effect of genetic engineering</i>	449
<i>Problems in detecting genetic manipulations in athletes</i>	450
<i>Ethical dilemma</i>	450
Gene therapy patents	450
CRISP/Cas9 patents	451
11. Markets for Gene Therapy	453
Introduction	453
Gene therapy markets in various regions of the world	453
Gene therapy markets according to therapeutic areas	454
Cancer gene therapy market	454
Markets for gene therapy of genetic disorders	454
Markets for DNA vaccines	455
DNA vaccines markets according to technologies	455
DNA vaccines markets according to therapeutic indications	456
DNA vaccines markets according to geographical areas	456
Competing treatments	457
Antisense	457
RNAi.....	457
Cell therapy	457
Strategies for developing gene therapy markets	458
<i>Collaboration with pharmaceutical companies</i>	458
<i>Collaboration with companies developing cell-based therapies</i>	458
<i>Collaboration with academic gene therapy centers</i>	458
<i>Developing safer and cost-effective gene medicines</i>	458
<i>Intellectual property and commercialization of gene therapy</i>	458
<i>Overcoming obstructions to the development of gene therapy</i>	459
Unmet needs in gene therapy	459
Promises and challenges for the development of gene therapy	460
Development of gene therapy market in China	460
Challenges of developing gene therapy in the USA	461
Challenges of developing gene therapy in the European Union	461
12. References	463

Tables

Table 1-1: Landmarks in development of gene therapy.....	23
Table 2-1: Classification of methods of gene therapy.....	35
Table 2-2: A comparison of various physical methods of gene transfer	37
Table 2-3: Experimental applications of gene transfer by electroporation	39
Table 2-4: Companies developing CRISPR technology	54
Table 2-5: An overview of characteristics of commonly used viral vectors	57
Table 2-6: Companies using viral vectors.....	71
Table 2-7: Companies using nonviral vectors	90
Table 2-8: Target organs for nonviral gene therapy methods.	92
Table 2-9: Potential routes for administration of DNA	100
Table 2-10: Companies with gene delivery devices/ technologies.....	102
Table 2-11: Strategies for targeted gene therapy	103
Table 2-12: Animal experimental studies of in vivo gene delivery with polymer systems.....	104
Table 2-13: Approaches to controlling gene expression in gene therapy	105
Table 2-14: Companies with regulated/targeted gene therapy and special techniques	108
Table 2-15: Potential applications of human germline genome modification	109
Table 2-16: Applications of molecular diagnostics in gene therapy	123
Table 2-17: Advantages of gene therapy compared with protein therapy	125
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	131
Table 3-2: Gene therapy strategies for osteoarthritis.....	132
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	139
Table 3-4: Indications for gastrointestinal gene therapy	146
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	148
Table 3-6: Companies involved in gene therapy of hematological disorders.....	158
Table 3-7: Techniques of gene transfer to the kidneys.....	164
Table 3-8: Gene therapy in animal experimental models of renal disease.....	166

Table 3-9: Applications of gene therapy in ophthalmological disorders.....	174
Table 3-10: Companies developing gene therapy for eye disorders	190
Table 3-11: Strategies for gene delivery to the lungs	194
Table 3-12: Companies developing gene therapy for pulmonary disorders	203
Table 4-1: Genetic disorders that are being investigated for gene therapy	216
Table 4-2: X-linked immunodeficiency disorders	218
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	223
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	241
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	257
Table 5-1: Strategies for cancer gene therapy	258
Table 5-2: Cell-based gene therapy for cancer	262
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines	270
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy	274
Table 5-5: Mutation compensation strategies used clinically	275
Table 5-6: Companies developing oncolytic viruses	290
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	294
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	300
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	302
Table 5-10: Gene therapy for malignant melanoma.....	303
Table 5-11: Clinical trials of gene therapy for prostate cancer	308
Table 5-12: Companies involved in cancer gene therapy.....	313
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	317
Table 6-2: Methods of gene transfer as applied to neurologic disorders	318
Table 6-3: Gene therapy techniques applicable to Parkinson disease	324
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	332
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	341
Table 6-6: Gene therapy strategies for vasospasm.....	342
Table 6-7: Neuroprotective gene therapy in animal stroke models	343
Table 6-8: Experimental gene therapy approaches for relief of pain	352
Table 6-9: Companies involved in gene therapy of neurological disorders	360
Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	361
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	362
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	389
Table 8-1: Strategies for gene therapy of AIDS	392
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	403
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	409
Table 9-1: Geographical distribution of gene therapy clinical trials	414
Table 9-2: Opportunities and challenges for gene therapy and resources needed	420
Table 9-3: Potential applications of gene therapy in disorders of the nervous system	421
Table 10-1: Genes that may be used for performance enhancement	448
Table 11-1: Gene therapy market according to regions/countries – 2016 to 2026	453
Table 11-2: Gene therapy markets according to therapeutic areas – 2016 to 2026.....	454
Table 11-3: Cancer gene therapy market according to type of cancer - 2016 to 2026.....	454
Table 11-4: Gene therapy market for selected genetic disorders - 2016 to 2026.....	455
Table 11-5: DNA vaccines markets according to technologies - 2016 to 2026.....	455
Table 11-6: DNA vaccines markets according to therapeutic indications - 2016 to 2026.....	456
Table 11-7: DNA vaccines markets according to geographical areas - 2016 to 2026.....	456

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	25
Figure 1-2: Relationship of DNA, RNA and protein in the cell	29
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	41
Figure 2-3: A scheme of CRISPR/Cas9 gene editing	48
Figure 2-4: Categories of rAAV-based gene therapy strategies	60
Figure 2-5: Bacteria plus nanoparticles for drug delivery into cells	88
Figure 2-6: Schematic of suppression of gene expression by RNAi	120
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders	180
Figure 4-1: Targeted gene correction of α 1-antitrypsin deficiency by iPSCs	226
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	247
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	255
Figure 5-1: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	281
Figure 5-2: Gene therapy approaches for pancreatic cancer	310
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	326
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	345
Figure 9-1: Product development cycle in gene therapy.....	411
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	416
Figure 9-3: Proportions of various vectors used in gene therapy trials	416
Figure 10-1: Evaluation system of gene therapy clinical studies in Japan	434
Figure 11-1: Unmet needs in gene therapy	460